Results 41 to 50 of about 24,049 (149)
Head and Neck Cancer Immunotherapy: Overcoming Limitations and Enhancing Efficacy
Cancer Science, Volume 116, Issue 11, Page 2920-2928, November 2025.ICI‐included therapies are standard for R/M HNSCC patients. In particular, neoadjuvant ICI therapy shows promising clinical results even in nontreated resectable HNSCC patients. In addition, cancer vaccine, immune cell‐based therapy, immunomodulation therapy, and TME targeting therapy may combine with ICI.Hirofumi Shibata, Masashi Kuroki, Ryo Kawaura, Tatsuhiko Yamada, Ryota Iinuma, Hiromasa Ishihara, Hiroshi Okuda, Kenichi Mori, Takenori Ogawa +8 morewiley +1 more sourceFirst-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis [PDF]
, 2021 Katsuyuki Hotta, Makoto Nishio, Haruhiro Saito, Isamu Okamoto, Yasuharu Nakahara, Hidetoshi Hayashi, Manabu Hayama, Peter J. Laud, Haiyi Jiang, Luis Paz‐Ares, Koichi Azuma +10 moreopenalex +1 more sourceData from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
, 2023 Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de los Reyes, Craig Barker, Jessica Whiteley, Robert I. Haddad, Lisa Licitra, Robert L. Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Ricard Mesı́a +24 moreopenalex +1 more sourceLBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) [PDF]
, 2022 Laurence Buisseret, Delphine Loirat, P. Aftimos, Kevin Punie, Christian Maurer, Véronique Debien, Ana Sofia Gonçalves, François Ghiringhelli, D. P. Taylor, Florian Clatot, T.F.A. van den Mooter, J-M Ferrero, Hervé Bonnefoi, J-L. Canon, François P. Duhoux, Fernando Bazán, Paulus Kristanto, Evandro de Azambuja, Michail Ignatiadis, Martine Piccart +19 moreopenalex +1 more sourceDurvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 ADRIATIC Trial
Cancer Science, Volume 116, Issue 11, Page 3171-3184, November 2025.This Japan subgroup analysis of the global phase 3 ADRIATIC trial showed that consolidation durvalumab versus placebo improves outcomes, and is well tolerated, in patients with limited‐stage small‐cell lung cancer following concurrent chemoradiotherapy comprising cisplatin or carboplatin‐based chemotherapy and once‐daily or twice‐daily radiotherapy ...Yoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, Koichi Azuma, Kyoichi Okishio, Hirokazu Ogino, Yoshitsugu Horio, Satoshi Oizumi, Manabu Hayama, Masahiro Nii, Masaya Harada, Helen Mann, Yuka S. Olivo, Haiyi Jiang, Suresh Senan +14 morewiley +1 more sourceData from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
, 2023 Tina Cascone, Gozde Kar, Jonathan Spicer, Rosario García-Campelo, Walter Weder, Davey B. Daniel, David R. Spigel, Maen Hussein, Julien Mazières, Júlio Oliveira, Edwin Yau, Alexander I. Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin‐Yang Cheng, Ying Zheng, Jorge Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez‐Canales, Vancheswaran Gopalakrishnan, Bret R. Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M. Forde +27 moreopenalex +1 more sourceSystemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 11, Page 1881-1894, November 2025.When managing psoriasis, induced or exacerbated by ICI therapy for cancer, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis and the potential impact on ICI efficacy. No direct, high‐level evidence exists to address these concerns.Kim A. Papp, Luis Puig, Jennifer Beecker, Vinod Chandran, Joël Claveau, Javier Cortés, Jan Dutz, Noah I. Hornick, Rosalyn A. Juergens, Barbara Melosky, Anisha B. Patel, Maxwell B. Sauder, Sandeep Sehdev, Vincent Sibaud, Stephanie L. Snow +14 morewiley +1 more source5PSQ-024 Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non-small-cell lung cancer (LA-NSCLC) [PDF]
, 2022 Z Rodríguez Fernández, B Távara Silva, B. Matilla Fernández, X Fernández-Sala, A Vélez Blanco, JC Sáez Hortelano, C De Castro Avedillo, R Varela Fernández, A Martín Sanz, C Guindel Jiménez, C Arenós Monzó +10 moreopenalex +1 more source
